CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
JERSEY CITY, N.J., April 06, 2016 -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the 15th Annual Needham Healthcare Conference at The Westin Grand Central Hotel in New York City on Wednesday, April 13, 2016 at 12:10 p.m. ET.
A live webcast will be available on the investors section of the Company's website: www.scynexis.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.
About SCYNEXIS
SCYNEXIS is a pharmaceutical company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and IV drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. For more information, visit www.scynexis.com.
CONTACT: Media Relations Heather Savelle MacDougall Biomedical Communications Tel: 781.235.3060 [email protected] Investor Relations Susan Kim Argot Partners Tel: 212-203-4433 [email protected]
